Intellia Therapeutics, Inc.
NTLA
$8.50
$0.4255.26%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 29.15% | 41.30% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 29.15% | 41.30% | |||
| Cost of Revenue | -7.23% | -5.27% | |||
| Gross Profit | 11.73% | 8.98% | |||
| SG&A Expenses | -10.59% | 6.37% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.96% | -2.96% | |||
| Operating Income | 11.46% | 5.75% | |||
| Income Before Tax | 11.30% | 5.02% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 11.30% | 5.02% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.30% | 5.02% | |||
| EBIT | 11.46% | 5.75% | |||
| EBITDA | 11.63% | 5.83% | |||
| EPS Basic | 12.71% | 5.82% | |||
| Normalized Basic EPS | 12.23% | 5.95% | |||
| EPS Diluted | 12.71% | 5.82% | |||
| Normalized Diluted EPS | 12.23% | 5.95% | |||
| Average Basic Shares Outstanding | 1.62% | 0.84% | |||
| Average Diluted Shares Outstanding | 1.62% | 0.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||